CLIMB BIO, INC. Restructuring and Related Cost, Incurred Cost
CLIMB BIO, INC. (CLYM) reported Restructuring and Related Cost, Incurred Cost of $2.25 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostIncurredCost · last filed 2025-03-25
- CLIMB BIO, INC. restructuring and related cost, incurred cost for the quarter ending 2024-12-31 was $0.00.
- CLIMB BIO, INC. restructuring and related cost, incurred cost for the quarter ending 2024-09-30 was $2.23M, a 1081.48% increase year-over-year.
- CLIMB BIO, INC. restructuring and related cost, incurred cost for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- CLIMB BIO, INC. restructuring and related cost, incurred cost for the quarter ending 2024-03-31 was $20.00K, a 99.70% decline year-over-year.
- CLIMB BIO, INC. restructuring and related cost, incurred cost for fiscal 2024 was $2.25M, a 74.92% decline from fiscal 2023.
- CLIMB BIO, INC. restructuring and related cost, incurred cost for fiscal 2023 was $8.98M.
| Period end | Restructuring and Related Cost, Incurred Cost 3 month | Restructuring and Related Cost, Incurred Cost 6 month | Restructuring and Related Cost, Incurred Cost 9 month | Restructuring and Related Cost, Incurred Cost 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2025-03-25 | $2.23M derived: sum of 2 quarters · filed 2025-03-25 | $2.23M derived: sum of 3 quarters · filed 2025-03-25 | $2.25M 10-K · filed 2025-03-25 |
| 2024-09-30 | $2.23M 10-Q · filed 2024-11-12 | $2.23M derived: sum of 2 quarters · filed 2024-11-12 | $2.25M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-11-12 | $20.00K derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2024-03-31 | $20.00K 10-Q · filed 2024-11-12 | |||
| 2023-12-31 | $8.98M 10-K · filed 2025-03-25 | |||
| 2023-09-30 | $189.00K 10-Q · filed 2023-11-14 | $588.00K derived: sum of 2 quarters · filed 2023-11-14 | $7.37M derived: sum of 3 quarters · filed 2023-11-14 | |
| 2023-06-30 | $399.00K 10-Q · filed 2023-11-14 | $7.18M derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2023-03-31 | $6.78M 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |